EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model

Robert M DiBlasi, Hattie KenKnight, Niko Kontoudios, Dale Farkas, Mohammad A M Momin, Felicia Hall, Michael Hindle, Worth Longest

Pharmaceutical Research · 2024

DOI: 10.1007/s11095-024-03754-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Robert M DiBlasi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, 1900 Ninth Ave, Seattle, WA, 98101, USA. robert.diblasi@seatt…. Hauptthemen laut MEDLINE: Aerosols, Powders, Pulmonary Surfactants, Respiratory Distress Syndrome, Newborn. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AerosolsPowdersPulmonary SurfactantsRespiratory Distress Syndrome, NewbornAnimalsRabbitsAdministration, InhalationDisease Models, AnimalDry Powder InhalersLungPhospholipidsAnimals, Newborn

Stichwörter der Autor:innen

infant aerosol therapyrespiratory distress syndromesurfactant aerosolsurfactant replacement therapysynthetic lung surfactant

Substanzen

AerosolsPhospholipidsPowdersPulmonary Surfactants

Autor:innen und Institutionen

  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, 1900 Ninth Ave, Seattle, WA, 98101, USA. robert.diblasi@seattlechildrens.org.
  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, 1900 Ninth Ave, Seattle, WA, 98101, USA.
  • Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, USA.
  • Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

DiBlasi, R. M., KenKnight, H., Kontoudios, N., Farkas, D., Momin, M. A. M., Hall, F., Hindle, M., & Longest, W. (2024). Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03754-7

Vancouver

DiBlasi RM, KenKnight H, Kontoudios N, Farkas D, Momin MAM, Hall F, et al. Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03754-7

BibTeX
@article{DiBlasi2024,
  author = {DiBlasi, Robert M and KenKnight, Hattie and Kontoudios, Niko and Farkas, Dale and Momin, Mohammad A M and Hall, Felicia and Hindle, Michael and Longest, Worth},
  title = {Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model},
  journal = {Pharmaceutical Research},
  year = {2024},
  doi = {10.1007/s11095-024-03754-7}
}
Kostenlos starten →